Home > Boards > US Listed > Medical - Drugs > Flexion Therapeutics, Inc. (FLXN)

News: $FLXN Flexion Therapeutics Names Christina Willwerth Chief

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
whytestocks Member Profile
Member Level 
Followed By 108
Posts 14,757
Boards Moderated 2
Alias Born 06/04/18
160x600 placeholder
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 11/6/2020 4:30:00 PM
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire Inc. - 11/5/2020 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2020 4:03:18 PM
Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire Inc. - 11/4/2020 4:01:00 PM
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020 GlobeNewswire Inc. - 10/29/2020 4:30:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2020 7:06:10 AM
Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million GlobeNewswire Inc. - 10/13/2020 6:59:10 AM
Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa GlobeNewswire Inc. - 10/8/2020 4:30:10 PM
Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting GlobeNewswire Inc. - 10/5/2020 9:00:10 AM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 10/2/2020 4:30:10 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/21/2020 3:28:12 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 9/11/2020 4:21:53 PM
Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference GlobeNewswire Inc. - 9/9/2020 4:30:10 PM
Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial GlobeNewswire Inc. - 9/8/2020 4:30:10 PM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 9/4/2020 4:30:10 PM
Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference GlobeNewswire Inc. - 9/3/2020 4:30:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2020 4:48:13 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/20/2020 4:46:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/19/2020 5:01:03 PM
Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors GlobeNewswire Inc. - 8/19/2020 9:00:10 AM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 8/7/2020 4:30:10 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 4:23:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2020 4:07:09 PM
Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire Inc. - 8/5/2020 4:01:10 PM
Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 GlobeNewswire Inc. - 7/30/2020 4:30:10 PM
whytestocks Member Level  Tuesday, 01/22/19 05:01:17 PM
Re: None
Post # of 69 
News: $FLXN Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer

BURLINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009, and she most recently served as the company’s Senior Vice President...

Got this from https://marketwirenews.com/news-releases/flexion-therapeutics-names-christina-willwerth-chief-strategy-officer-7449860.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences